藍帆醫療(002382.SZ):控股股東2020年非公開發行可交換公司債將進入換股期
格隆匯 12 月 12日丨藍帆醫療(002382.SZ)公佈,公司的控股股東淄博藍帆投資有限公司(“藍帆投資”)於2020年6月15日發行了藍帆投資2020年非公開發行可交換公司債券。本次可交換債券簡稱為“20藍帆E1”,債券代碼為“117164”,發行規模為2億元人民幣,債券期限為3年,最終票面利率為3%,初始換股價格為24.15元/股。
根據有關規定和《淄博藍帆投資有限公司2020年非公開發行可交換公司債券募集説明書》的約定,此次可交換債券換股期為自發行結束日滿6個月後的第一個交易日(2020年12月16日)起至可交換債券摘牌日(2023年6月14日)止。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.